FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2494094204> ?p ?o ?g. }

• W2494094204 endingPage "2325967116S0018" @default.
• W2494094204 startingPage "2325967116S0018" @default.
• W2494094204 abstract "Objectives: We present the early results from the “Multicenter Orthopaedic Outcome Network Early Anti-inflammatory Treatment in Patients with Acute ACL Tear and Painful Effusions” (MOON-AAA) clinical trial (figure 1). This trial allows for a well controlled prospective cohort of patients with isolated ACL injury at risk for OA. We compared the effect of a single versus a repeated dosage of Kenalog within the first two weeks after ACL injury and its effect on chondral degradation in the first 4 weeks prior to surgical reconstruction of the ACL. Methods: 49 patients with isolated ACL tears were enrolled. Knee joints were aspirated and patients received an injection with 40 mg Kenalog either within 4 days, 10 days, both time points or not at all (saline injection control). Serum, synovial fluid and urine were collected at 3 time points. Permutated block randomization, triple blinding, independent monitoring and standardized x-ray was performed to comply with GCP standards. Patient reported outcomes were collected at 6 time points up to 6 months post-ACL reconstruction(IKDC, KOOS and Marx activity level). A standardized synovial fluid biomarker panel was analyzed according to OARSI guidelines. Statistical analysis were performed using SAS mixed models analysis. Results: Serum analysis shows significant change after injury. Chondrodegradatory markers such as CTX-II, MMP-1 and MMP-3 as well as COMP indicate a progressive destruction of chondral matrix and collagen breakdown . There is a dramatic (250%) increase of CTX-II in the first 4 weeks. Matrix proteins such as MMP-1 and 3 as well as COMP show an initial increase and then a steep decline (see figure 1). Inflammatory markers (IL-1 alpha, IL-1beta, IRAP) show a decline from the time of injury. IL-1 alpha, however shows a dramatic uptake after week 2. This longitudinal data confirms a dramatic onset of early osteoarthritic biomarker profiles immediately after ACL injury as measured in synovial fluid.The administration of 40 mg of Kenalog significantly changes this dynamic. CTX-II shows a dramatic reduction and stays close to baseline levels over the course of 4 weeks pre-operatively. COMP and MMP-1 show a significantly lesser decline.There is no significant difference in the effect of Kenalog if given within 4 days of injury or within 2 weeks. There is a statistical trend indicating that a repeated dose of Kenalog may be more efficient in normalizing the biomarker levels. No AE’s, infections were observed. Two of 49 patients suffered a retear at 6 months upon return to activities. Conclusion: Our data show that posttraumatic osteoarthritis begins at the time of injury and results early on in dramatic matrix changes in the knee joint. An early intervention with an antiinflammatory agent, such as Kenalog, maybe be able to prevent some of these changes observed.We do not currently know if the early intervention results in meaningful clinical differences in overall outcome. Further follow-up will answer this question. However, it is encouraging that a simple early intervention is able to affect early chondral degeneration. Should the early intervention with Kenalog lead to meaningful changes in outcome at 2 or 6 years the current treatment paradigm for ACL injured patients may have to be changed." @default.
• W2494094204 created "2016-08-23" @default.
• W2494094204 creator A5018971052 @default.
• W2494094204 creator A5021136719 @default.
• W2494094204 creator A5028439043 @default.
• W2494094204 creator A5042320697 @default.
• W2494094204 creator A5046700569 @default.
• W2494094204 creator A5051427354 @default.
• W2494094204 creator A5071631262 @default.
• W2494094204 date "2016-07-01" @default.
• W2494094204 modified "2023-10-14" @default.
• W2494094204 title "Multicenter Orthopaedic Outcome Network Early Anti-inflammatory Treatment in Patients with Acute ACL Tear” (MOON-AAA) Clinical Trial" @default.
• W2494094204 doi "https://doi.org/10.1177/2325967116s00189" @default.
• W2494094204 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4968361" @default.
• W2494094204 hasPublicationYear "2016" @default.
• W2494094204 type Work @default.
• W2494094204 sameAs 2494094204 @default.
• W2494094204 citedByCount "1" @default.
• W2494094204 countsByYear W24940942042023 @default.
• W2494094204 crossrefType "journal-article" @default.
• W2494094204 hasAuthorship W2494094204A5018971052 @default.
• W2494094204 hasAuthorship W2494094204A5021136719 @default.
• W2494094204 hasAuthorship W2494094204A5028439043 @default.
• W2494094204 hasAuthorship W2494094204A5042320697 @default.
• W2494094204 hasAuthorship W2494094204A5046700569 @default.
• W2494094204 hasAuthorship W2494094204A5051427354 @default.
• W2494094204 hasAuthorship W2494094204A5071631262 @default.
• W2494094204 hasBestOaLocation W24940942041 @default.
• W2494094204 hasConcept C126322002 @default.
• W2494094204 hasConcept C141071460 @default.
• W2494094204 hasConcept C142724271 @default.
• W2494094204 hasConcept C188816634 @default.
• W2494094204 hasConcept C204243189 @default.
• W2494094204 hasConcept C204787440 @default.
• W2494094204 hasConcept C2771230 @default.
• W2494094204 hasConcept C2776164576 @default.
• W2494094204 hasConcept C2776268809 @default.
• W2494094204 hasConcept C2778275304 @default.
• W2494094204 hasConcept C2778434673 @default.
• W2494094204 hasConcept C2781170992 @default.
• W2494094204 hasConcept C535046627 @default.
• W2494094204 hasConcept C71924100 @default.
• W2494094204 hasConceptScore W2494094204C126322002 @default.
• W2494094204 hasConceptScore W2494094204C141071460 @default.
• W2494094204 hasConceptScore W2494094204C142724271 @default.
• W2494094204 hasConceptScore W2494094204C188816634 @default.
• W2494094204 hasConceptScore W2494094204C204243189 @default.
• W2494094204 hasConceptScore W2494094204C204787440 @default.
• W2494094204 hasConceptScore W2494094204C2771230 @default.
• W2494094204 hasConceptScore W2494094204C2776164576 @default.
• W2494094204 hasConceptScore W2494094204C2776268809 @default.
• W2494094204 hasConceptScore W2494094204C2778275304 @default.
• W2494094204 hasConceptScore W2494094204C2778434673 @default.
• W2494094204 hasConceptScore W2494094204C2781170992 @default.
• W2494094204 hasConceptScore W2494094204C535046627 @default.
• W2494094204 hasConceptScore W2494094204C71924100 @default.
• W2494094204 hasIssue "7_suppl4" @default.
• W2494094204 hasLocation W24940942041 @default.
• W2494094204 hasLocation W24940942042 @default.
• W2494094204 hasOpenAccess W2494094204 @default.
• W2494094204 hasPrimaryLocation W24940942041 @default.
• W2494094204 hasRelatedWork W2078188784 @default.
• W2494094204 hasRelatedWork W2493728645 @default.
• W2494094204 hasRelatedWork W2520671719 @default.
• W2494094204 hasRelatedWork W2581365522 @default.
• W2494094204 hasRelatedWork W2582497603 @default.
• W2494094204 hasRelatedWork W2917760486 @default.
• W2494094204 hasRelatedWork W2991414051 @default.
• W2494094204 hasRelatedWork W3169152838 @default.
• W2494094204 hasRelatedWork W4309013773 @default.
• W2494094204 hasRelatedWork W4385412619 @default.
• W2494094204 hasVolume "4" @default.
• W2494094204 isParatext "false" @default.
• W2494094204 isRetracted "false" @default.
• W2494094204 magId "2494094204" @default.
• W2494094204 workType "article" @default.